Benitec Biopharma Inc. (BNTC) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, BNTC carries an RQD Score of 30 and a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars score as follows: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield -7.66%), Whale 13F Flow 3/20, Insider Conviction 3/20, Macro Regime Fit 6/20 (Beta 1.0), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillars are institutional flow and insider conviction, each at 3 out of 20. The cash engine score is also low, consistent with the negative ROIC and negative free cash flow yield. The forensic balance sheet pillar is the relative strength, with a Debt/Equity of 0.5 and an Altman Z of 2.5, though the Piotroski F of 2/9 signals weak financial health across the checks. For a prospective investor evaluating the stock today, the rating frames the current setup as high forensic risk. Upside would depend on the catalysts described below converting into sustained cash generation, which the source data does not yet show. This brief is analytical and educational, not personalized advice.

Benitec Biopharma Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the source profile, the company operates with a market capitalization of $0.3B. The source data does not specify its products, customers, or revenue model. Reported revenue in the SEC financials is $0.0M across all listed periods.

Per the SEC financials, operating losses widened from $-19.1M in FY 2023 to $-41.8M in FY 2025, and net income losses followed a similar path. Gross, operating, and net margins are each reported as 0% in the market data. The Roarable RQD rating cites an ROIC of -35%, an Altman Z-Score of 2.5, and a Piotroski F-Score of 2/9. Reported cash rose to $188.8M in FY 2025 from $78.3M in FY 2024, while debt is listed as N/A in the source periods.

Per the recent news and catalysts feed, the most prominent items are: a regulatory update following a Type C meeting with the FDA regarding the BB-301 pivotal study (flagged YELLOW, MARKET WIRE); a TradingView report of a 12-month price target raised to $24.33, implying 171% upside (GREEN, CATALYST); Raymond James initiating coverage with an Outperform rating and a $14 price target (GREEN, CATALYST); and a Stock Titan report that every patient in the company's study responded to an experimental treatment for a disease that weakens swallowing (YELLOW, MARKET WIRE). A Benzinga initiation roundup also references BNTC (GREEN, CATALYST). Risk watch items: the feed includes only headline-level summaries and does not provide trial sample sizes, timelines, or regulatory terms. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations. Investors should watch whether the pivotal-study regulatory path, referenced in the news feed, affects the company's ability to fund operations given its reported negative free cash flow, since the source does not describe the company's funding structure beyond reported cash.

• What is the funding runway given reported FY 2025 free cash flow of $-23.6M against $188.8M in cash?
• What are the timeline, endpoints, and enrollment details of the BB-301 pivotal study referenced in the FDA regulatory update?
• Why are revenue, EPS, and debt reported as $0.0M or N/A across all periods, and what is the company's primary business model?
• What drove the reported cash increase from $78.3M to $188.8M between FY 2024 and FY 2025?
• What analyst consensus and holder data would confirm or challenge the Raymond James initiation and the cited price target?